JP7634231B2 - Ｐａｎ－ノイラミニダーゼ阻害抗体 - Google Patents

Ｐａｎ－ノイラミニダーゼ阻害抗体 Download PDF

Info

Publication number
JP7634231B2
JP7634231B2 JP2021571517A JP2021571517A JP7634231B2 JP 7634231 B2 JP7634231 B2 JP 7634231B2 JP 2021571517 A JP2021571517 A JP 2021571517A JP 2021571517 A JP2021571517 A JP 2021571517A JP 7634231 B2 JP7634231 B2 JP 7634231B2
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
antigen
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021571517A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535523A5 (https=
JP2022535523A (ja
JPWO2020243572A5 (https=
Inventor
アリ エレベディ，
フロリアン クラマー，
イアン ウィルソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL
Publication of JP2022535523A publication Critical patent/JP2022535523A/ja
Publication of JP2022535523A5 publication Critical patent/JP2022535523A5/ja
Publication of JPWO2020243572A5 publication Critical patent/JPWO2020243572A5/ja
Priority to JP2025014697A priority Critical patent/JP2025090568A/ja
Application granted granted Critical
Publication of JP7634231B2 publication Critical patent/JP7634231B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2021571517A 2019-05-31 2020-05-29 Ｐａｎ－ノイラミニダーゼ阻害抗体 Active JP7634231B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025014697A JP2025090568A (ja) 2019-05-31 2025-01-31 Ｐａｎ－ノイラミニダーゼ阻害抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855358P 2019-05-31 2019-05-31
US62/855,358 2019-05-31
PCT/US2020/035323 WO2020243572A2 (en) 2019-05-31 2020-05-29 Pan-neuraminidase inhibiting antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025014697A Division JP2025090568A (ja) 2019-05-31 2025-01-31 Ｐａｎ－ノイラミニダーゼ阻害抗体

Publications (4)

Publication Number Publication Date
JP2022535523A JP2022535523A (ja) 2022-08-09
JP2022535523A5 JP2022535523A5 (https=) 2023-06-05
JPWO2020243572A5 JPWO2020243572A5 (https=) 2023-06-05
JP7634231B2 true JP7634231B2 (ja) 2025-02-21

Family

ID=73552980

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021571517A Active JP7634231B2 (ja) 2019-05-31 2020-05-29 Ｐａｎ－ノイラミニダーゼ阻害抗体
JP2025014697A Pending JP2025090568A (ja) 2019-05-31 2025-01-31 Ｐａｎ－ノイラミニダーゼ阻害抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025014697A Pending JP2025090568A (ja) 2019-05-31 2025-01-31 Ｐａｎ－ノイラミニダーゼ阻害抗体

Country Status (4)

Country Link
US (1) US12509503B2 (https=)
EP (1) EP3980441A4 (https=)
JP (2) JP7634231B2 (https=)
WO (1) WO2020243572A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025090568A (ja) * 2019-05-31 2025-06-17 ワシントン ユニバーシティ Ｐａｎ－ノイラミニダーゼ阻害抗体

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023201306A1 (en) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. Compositions for preventing or treating influenza infections
CN119119281B (zh) * 2024-09-02 2025-12-05 中山大学·深圳 抗神经氨酸酶的单克隆抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010503668A (ja) 2006-09-15 2010-02-04 フラウンホーファー ユーエスエー， インコーポレイテッド インフルエンザ抗体、組成物、および関連する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8734803B2 (en) * 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
CA2858347C (en) * 2011-12-05 2020-07-07 New York University V1v2 immunogens
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
WO2016124682A1 (en) * 2015-02-05 2016-08-11 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza neuraminidase
EP3980441A4 (en) * 2019-05-31 2023-02-22 Washington University PAN-NEURAMINIDASE INHIBITING ANTIBODIES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010503668A (ja) 2006-09-15 2010-02-04 フラウンホーファー ユーエスエー， インコーポレイテッド インフルエンザ抗体、組成物、および関連する方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025090568A (ja) * 2019-05-31 2025-06-17 ワシントン ユニバーシティ Ｐａｎ－ノイラミニダーゼ阻害抗体

Also Published As

Publication number Publication date
JP2022535523A (ja) 2022-08-09
WO2020243572A3 (en) 2021-01-07
US12509503B2 (en) 2025-12-30
US20220242935A1 (en) 2022-08-04
EP3980441A4 (en) 2023-02-22
EP3980441A2 (en) 2022-04-13
WO2020243572A2 (en) 2020-12-03
JP2025090568A (ja) 2025-06-17

Similar Documents

Publication Publication Date Title
DK2734545T3 (en) NEUTRALIZING ANTI-INFLUENZA A VIRUS ANTIBODIES AND APPLICATIONS THEREOF
JP2025090568A (ja) Ｐａｎ－ノイラミニダーゼ阻害抗体
ES2894777T3 (es) Neutralización de moléculas de unión anti-influenza y usos de las mismas
JP6423550B2 (ja) 広域スペクトルモノクローナル抗ＦｌｕＢ抗体およびその使用
CN102216327A (zh) 中和抗甲型流感病毒抗体及其用途
US20200354436A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
TWI728272B (zh) 中和性抗體的高通量篩選方法、由該方法製備之中和性抗體，以及其用途
Kalenik et al. Influenza prevention and treatment by passive immunization.
TW202204398A (zh) 抗ＳＡＲＳ－ＣｏＶ－２單株抗體
US12077574B2 (en) Methods and composition for neutralization of influenza
CN111094335B (zh) 广泛中和的抗流感单克隆抗体及其用途
US8460670B2 (en) Fully human influenza M2 specific antibodies
EP4100054A1 (en) Antibodies protective against influenza b
HK1250725B (zh) 中和抗流感结合分子及其用途
EP3122772A1 (en) Chimerization and characterization of a monoclonal antibody with potent neutralizing activity across multiple influenza a h5n1 clades

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230526

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240806

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241227

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250131

R150 Certificate of patent or registration of utility model

Ref document number: 7634231

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150